Search
02/10/2024
Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies
Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Ngantcha, M, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB. Treatment-emergent Candida infections in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis treated with ixekizumab: an integrated safety analysis of 25 clinical studies. Expert Opinion On Drug Safety. 2024; 23(10)DOI:10.1080/14740338.2024.2399092. PMID:39234767. IF:3.100(Q2/4D).
02/10/2024
Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting
Doblas, JJG, García-Moll, X, Freire, RB, Juanatey, CG, Morillas, M, Muñoz, AV, Escobar, C. Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting. Future Cardiology. 2024; 20(13)DOI:10.1080/14796678.2024.2343550. PMID:39439239. IF:(Q/D).
01/10/2024
Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?
Saposnik, G, Monreal, E, Medrano, N, García-Domínguez, JM, Querol, L, Meca-Lallana, JE, Landete, L, Salas, E, Meca-Lallana, V, García-Arcelay, E, Agüera-Morales, E, Martínez-Yélamos, S, Gómez-Ballesteros, R, Maurino, J, Villar, LM, Caminero, AB. Does serum neurofilament light chain measurement influence therapeutic decisions in multiple sclerosis?. Multiple Sclerosis and Related Disorders. 2024; 90DOI:10.1016/j.msard.2024.105838. PMID:39216454. IF:2.900(Q2/4D).
01/10/2024
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
Allen, JA, Lin, J, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, KG, Hewamadduma, C, Hofman, E, Hussain, YM, Kuwabara, S, Le Masson, G, Leypoldt, F, Chang, T, Lipowska, M, Lowe, M, Lauria, G, Querol, L, Simu, MA, Suresh, N, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA, van Doorn, PA. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. LANCET NEUROLOGY. 2024; 23(10)DOI:10.1016/S1474-4422(24)00309-0. PMID:39304241. IF:45.500(Q1/1D).